Barbara A. Brown-Elliott MS, MT(ASCP), SM is currently a Professor of Microbiology and Associate Director of the Mycobacteria/Nocardia Laboratory at the University of Texas Health Science Center at Tyler (UTHSCT). She has supervised the UTHSCT laboratory since 1988. Before coming to the UTHSCT, she served as a clinical microbiology supervisor, a consultant for a clinical microbiology reference laboratory, and a microbiology Adjunct Professor in medical technology. She is the author and/or co-author of more than 300 peer-reviewed articles and chapters on nontuberculous mycobacteria (NTM), Nocardia and other aerobic actinomycetes, with over 100 publications on antimicrobial susceptibility testing and resistance mechanisms. She has been a member of the American Society for Microbiology (ASM) since 1978 and is a frequent speaker at local, national, and international meetings. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antimycobacterial Susceptibility Subcommittee (Currently revised as the Antimycobacterial Susceptibility Working Group). She is a 2009 recipient of the Becton Dickinson Gardner Middlebrook Award for Outstanding Work in Mycobacteriology, the ASM Scherago-Rubin Award for outstanding clinical microbiologist in 2013, and an ASM Distinguished Lecturer from 2019-2020. 

Dr. Marie-Claire Rowlinson received her undergraduate and doctoral degrees in Medical Microbiology in the UK and then completed a post-doctoral fellowship in Medical and Public Health Laboratory Microbiology at University of California, Los Angeles. Following the fellowship, Dr. Rowlinson worked with the Association of Public Health Laboratories (APHL) in their Global Health program, building laboratory capacity in Eastern Europe, Africa, and the Caribbean. From 2012 to 2021, she held the position of Assistant Laboratory Director and CLIA Laboratory Director at the Florida Department of Health, Bureau of Public Health Laboratories in Jacksonville. Since September 2021, Dr. Rowlinson is the Chief of Bacterial Diseases at the Wadsworth Center, New York State Department of Health. Dr. Rowlinson’s expertise is in infectious disease diagnostics, in particular molecular diagnostics, tuberculosis, and global health. She continues to work closely with the Association of Public Health Laboratories and is the Chair of the APHL Infectious Diseases Committee and a Member of the TB Subcommittee. She also continues to work with APHL on an international level, consulting with the Global Health program, most recently working with the Ukraine Ministry of Health. Dr. Rowlinson is a Member of the College of American Pathologists Microbiology Committee.

Romney Humphries, PhD D(ABMM) is a Professor in the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center, where she is the Director of Infectious Diseases Laboratories and the Director of the Division of Laboratory Medicine.

Romney received her PhD in bacteriology from the University of Calgary, Canada and a clinical and public health microbiology CPEP fellowship at UCLA.

She worked at UCLA as an assistant professor in Pathology and laboratory medicine from 2010–2017 and was the section chief for clinical microbiology from 2012–2017. She then took on the role of Chief Scientific Officer at Accelerate Diagnostics from 2017–2020 before returning to academia in 2020, at VUMC.

Dr. Humphries is passionate about clinical microbiology and antimicrobial resistance in particular. She is a champion for the development of novel diagnostic tests for infectious diseases to transform how patients with infections are managed.

Dr. Humphries is an editor for the Journal of Clinical Microbiology and Clinical Infectious Diseases. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antibiotic Susceptibility Testing (AST) Subcommittee, the College of American Pathologists (CAP) Microbiology Committee, the American Society for Microbiology (ASM) Professional Practices Committee, and vice-chair of the Infectious Diseases Society of America Diagnostics Committee.

She is the author of over 150 peer-reviewed articles, numerous book chapters, and has lectured globally on the topics of antimicrobial resistance and diagnostic microbiology. Dr. Humphries is the 2022 ASM awardee for Leadership and Research in Clinical Microbiology. She is a fellow of the American Academy of Microbiology, and the Infectious Diseases Society of America.

Romney Humphries, PhD D(ABMM) is a Professor in the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center, where she is the Director of Infectious Diseases Laboratories and the Director of the Division of Laboratory Medicine.

Romney received her PhD in bacteriology from the University of Calgary, Canada and a clinical and public health microbiology CPEP fellowship at UCLA.

She worked at UCLA as an assistant professor in Pathology and laboratory medicine from 2010–2017 and was the section chief for clinical microbiology from 2012–2017. She then took on the role of Chief Scientific Officer at Accelerate Diagnostics from 2017–2020 before returning to academia in 2020, at VUMC.

Dr. Humphries is passionate about clinical microbiology and antimicrobial resistance in particular. She is a champion for the development of novel diagnostic tests for infectious diseases to transform how patients with infections are managed.

Dr. Humphries is an editor for the Journal of Clinical Microbiology and Clinical Infectious Diseases. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antibiotic Susceptibility Testing (AST) Subcommittee, the College of American Pathologists (CAP) Microbiology Committee, the American Society for Microbiology (ASM) Professional Practices Committee, and vice-chair of the Infectious Diseases Society of America Diagnostics Committee.

She is the author of over 150 peer-reviewed articles, numerous book chapters, and has lectured globally on the topics of antimicrobial resistance and diagnostic microbiology. Dr. Humphries is the 2022 ASM awardee for Leadership and Research in Clinical Microbiology. She is a fellow of the American Academy of Microbiology, and the Infectious Diseases Society of America.

Dr. Bobenchik is a board certified clinical microbiologist with over 20 years of experience working in the laboratory. She is currently the Medical Director of Microbiology and Virology at Penn State Hershey Medical Center and Associate Professor of Pathology at Penn State College of Medicine. She has been a volunteer with CLSI since 2013.

Ms. Hindler has worked as a clinical microbiologist for over 50 years, including 40 years at UCLA Health System. Currently, she works as a consultant for the Los Angeles County Department of Public Health.  Janet has been a volunteer with CLSI for nearly 3 decades.

Romney Humphries, PhD D(ABMM) is a Professor in the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center, where she is the Director of Infectious Diseases Laboratories and the Director of the Division of Laboratory Medicine.

Romney received her PhD in bacteriology from the University of Calgary, Canada and a clinical and public health microbiology CPEP fellowship at UCLA.

She worked at UCLA as an assistant professor in Pathology and laboratory medicine from 2010–2017 and was the section chief for clinical microbiology from 2012–2017. She then took on the role of Chief Scientific Officer at Accelerate Diagnostics from 2017–2020 before returning to academia in 2020, at VUMC.

Dr. Humphries is passionate about clinical microbiology and antimicrobial resistance in particular. She is a champion for the development of novel diagnostic tests for infectious diseases to transform how patients with infections are managed.

Dr. Humphries is an editor for the Journal of Clinical Microbiology and Clinical Infectious Diseases. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antibiotic Susceptibility Testing (AST) Subcommittee, the College of American Pathologists (CAP) Microbiology Committee, the American Society for Microbiology (ASM) Professional Practices Committee, and vice-chair of the Infectious Diseases Society of America Diagnostics Committee.

She is the author of over 150 peer-reviewed articles, numerous book chapters, and has lectured globally on the topics of antimicrobial resistance and diagnostic microbiology. Dr. Humphries is the 2022 ASM awardee for Leadership and Research in Clinical Microbiology. She is a fellow of the American Academy of Microbiology, and the Infectious Diseases Society of America.

Dr. Bobenchik is a board certified clinical microbiologist with over 20 years of experience working in the laboratory. She is currently the Medical Director of Microbiology and Virology at Penn State Hershey Medical Center and Associate Professor of Pathology at Penn State College of Medicine. She has been a volunteer with CLSI since 2013.

Dr. Barb Jones was appointed as Chief Executive Officer of CLSI on May 15, 2022. She is the third CEO in CLSI's 54-year history. Dr. Jones’ experience includes operations leadership, laboratory management, pharmaceutical and quality standards development, regulatory policy, and business development at both the national and international levels. Prior to her role as CLSI’s CEO, Barb was Senior Vice President, Scientific Operations and Regulatory Affairs at Vyant Bio in San Diego, California.

In her role as Vice President at the United States Pharmacopeia (USP), Dr. Jones directed the work of more than 200 global scientists and oversaw the “Gold Standard” for reference materials for the US and more than 150 countries worldwide. As a scientist and researcher for the National Institute of Standards and Technology (NIST), she served as Science Advisor for the Biochemical Sciences Division, and was appointed by the NIST Director as Advisor to the US House of Representatives Committee on Science and Technology. In this role, she developed analytical techniques for lab-on-a-chip technology and coordinated the expansion of chemical and biological weapons counterterrorism standards for the US Department of Homeland Security.

Additionally, she has provided critical advisement on the viability of acquisitions and technologies, particularly in pharmaceutical and medical device and diagnostic development. She also has advised international policy makers, key scientists, and business leaders around the world on pharmaceutical standards, laboratory practices, proficiency, and regulatory compliance.

Dr. Jones received her Doctorate in Analytical Chemistry from Arizona State University and was awarded a prestigious National Research Council postdoctoral fellowship at NIST.

Katie Barnett is CLSI's Director of Membership and User Experience and has been with CLSI for the past 14 years. She previously held the positions of Membership Director and Manager of Membership and Marketing.

Jessica Tredway is CLSI's Customer Relationship Manager. Her responsibilities include building, retaining, maintaining, and fostering relationships between CLSI and its stakeholders, including members, customers, volunteers and vendors.

Dr. Budd received his PhD in Biometry and Health Information Systems from the University of Minnesota. His entire career has been directed toward improving clinical diagnostics in lung function, cardiac electrophysiology, home health monitoring and finally in vitro diagnostics (IVD). He was Principal Biostatistician at Beckman Coulter for 20 years from which he retired 2 years ago.

Besides an IVD biostatistical consulting practice, Dr. Budd actively participates in developing IVD international guidelines. This includes membership in the ISO TC212 working group 2 which published 17511 on metrological traceability and the IFCC working group on reference material commutability which published a series of papers on this topic. He also plays active roles in CLSI including as a member of the EP Expert Panel; as chair of the document development committees (DDC) for EP09 on measurement procedure comparison, EP12 on qualitative examinations and EP30 on commutable reference material; and as member of the DDCs for EP14 on processed sample commutability and for EP32 on metrological traceability.

Ms. Berte has a bachelor’s degree in Medical Technology and a master’s degree in Health Care Administration. In addition to being an ASCP-certified Medical Technologist, Specialist in Blood Banking, and Diplomate in Laboratory Management, she is also certified as a Quality Manager and Quality Auditor by the American Society for Quality.

Ms. Berte has been the author of numerous articles, chapters, and books and continues to provide learning programs on various aspects of laboratory quality management. She has volunteered for CLSI for 30 years and has served as chairholder and member of past and current CLSI document development committees and was one of the developers of the Method Navigator product you will see today.

Ms. Kern is a director of Standards Development and Project Administration at CLSI and has been apart of the organization for over three years. She has her Master’s degree in Medical Laboratory science and is an ASCP-certified Medical Laboratory Scientist. Prior to CLSI she spent 12 years working in an Immunology and Flow Cytometry medical laboratory. Her project focus has been on documents in Method Evaluation area. Ms. Kern has helped with the development and implementation of this novel product.

Virginia Litwin is a thought-leader in validation and standardization for flow cytometry. Bringing “Cytometry from Bench-to-Bedside” has been the focus of her professional activities since 1999 when she started working in translational medicine at Bristol-Myers Squibb. 

She co-founded the Flow Cytometry Community within the AAPS. This group published the first papers on flow cytometry method and instrument validation. She was a councilor for the International Society for the Advancement of Cytometry (ISAC) and the International Clinical Cytometry Society (ICCS). She serves on the ICCS Advocacy Committee whose mission is to interface with regulatory agencies and has been an invited speaker at FDA/NIST on many occasions.

Virginia is the chair of the Document Development Committee for the CLSI H62. She edited the book, Flow Cytometry in Drug Discovery and Development, as well as journal special issues: JIM- Flow Cytometry Biomarkers and Translational Medicine (2011); Cytometry Part B- Receptor Occupancy (2015); Cytometry Part B- Cytometry Advancing Next Generation Drug Development (2021).

After obtaining a Ph.D. in Virology/Immunology from the University of Iowa, Virginia joined Lewis Lanier at DNAX as a post-doctoral fellow where she identified the KIR receptor, KIR3DL1 (CD158E1). She has held leadership roles in several contract research organizations. Currently she is a Research Scientist at Charles River Laboratories in Québec, Canada.

https://www.linkedin.com/in/virginia-litwin-99869511

https://twitter.com/VirginiaLi...

Nithianandan Selliah’s professional work spans academia, the biotech/pharma sector and most recently CROs. His Ph.D. research at the University of Kentucky focused on the effect of epinephrine in the modulation of T cell activation. After his PhD, he joined Dr. Terri Finkel’s lab at National Jewish Medical center to study the mechanism of by stander killing of CD4 T cells by HIV. This worked continued at the Children’s Hospital of Philadelphia. Later he conducted pioneering research in CAR T-cells for HIV therapy under the mentorship of Dr. Richard Junghans at Roger Williams Medical Center in Providence, RI. He then moved to a Biotech company to identify biomarkers for lupus disease utilizing flow cytometry. He joined Celgene to work on a specific project to explore therapeutic potential of red blood cells derived from in vitro differentiation of HSCs.

In 2015, Dr. Selliah joined LabCorp drug development (formerly Covance) to help facilitate their expansion of flow cytometry supporting clinical drug development. He has developed and validated more than 10 flow cytometric methods which were deployed in numerous global clinical trials. His work has been represented at the International Clinical Cytometry Society (ICCS) Annual Course and the International Society for the Advancement of Cytometry’s annual meeting, CYTO. He has contributed to recommendation papers in Cytometry B and Current Protocols in Cytometry, and a chapter on receptor occupancy assays.

He is an active member of the ICCS Quality and Standards committee whose mission is to create educational modules for the international flow cytometry community on standardizing processes for flow cytometry assays, including reagent quality testing and instrument standardization.

Currently Dr. Selliah is the Global Head of Flow Cytometry at Cerba Research, where he leads a team of 12 scientists in developing and validating Flow cytometry assays for global clinical trials.